BioVentrix has received certification for CE marking its Revivent TC transcatheter ventricular enhancement system.
Following a myocardial infarction or heart attack, the Revivent TC system is designed to implant proprietary micro-anchor pairs to exclude scarred myocardium from the healthy tissue of the left ventricle.
“There is no doubt that LV volume reduction is an important therapy as it directly impacts the parameters that determine prognosis and survival, such as LV volume and ejection fraction. The impact of the Revivent TC system is achieved by transcatheter access to exclude the ischemic portion of the left ventricle from the healthy tissue,” says Lon Annest, chief medical officer of BioVentrix.
According to a press release, at two-year follow-up, patients have made improvements in their quality of life by 38%. The release states that the product’s clinical benefit has been proven to extend life for patients with a significant reduction of left ventricle end-systolic volume index (31%) and improvement of left ventricle ejection fraction (23%).
Accordig to the release, the Revivent TC System is the only interventional therapy that can consistently achieve this survival benefit in heart failure patients.
